Reata Pharmaceuticals Inc (NASDAQ:RETA) Director Cpmg Inc bought 200,000 shares of Reata Pharmaceuticals stock in a transaction dated Thursday, December 14th. The stock was acquired at an average cost of $24.79 per share, with a total value of $4,958,000.00. Following the completion of the acquisition, the director now directly owns 113 shares of the company’s stock, valued at approximately $2,801.27. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Reata Pharmaceuticals Inc (NASDAQ:RETA) opened at $25.10 on Friday. Reata Pharmaceuticals Inc has a one year low of $19.48 and a one year high of $40.88. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15.
Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). The firm had revenue of $12.60 million for the quarter, compared to analyst estimates of $12.54 million. The company’s revenue for the quarter was up .0% compared to the same quarter last year. sell-side analysts expect that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current year.
A number of equities research analysts have recently commented on the stock. Cowen reaffirmed a “buy” rating on shares of Reata Pharmaceuticals in a report on Thursday. Leerink Swann assumed coverage on shares of Reata Pharmaceuticals in a report on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 target price for the company. Jefferies Group assumed coverage on shares of Reata Pharmaceuticals in a report on Wednesday, August 30th. They issued a “buy” rating and a $44.00 target price for the company. ValuEngine cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, BidaskClub cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. Three equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company’s stock. Reata Pharmaceuticals presently has an average rating of “Hold” and an average price target of $54.71.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/12/17/cpmg-inc-buys-200000-shares-of-reata-pharmaceuticals-inc-reta-stock.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.